These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2900818)

  • 1. Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
    Viray R; Turlapaty P; Laddu A
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):153-61. PubMed ID: 2900818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
    Blanski L; Lutz J; Laddu A
    Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the beta-blocker therapy on neutrophil superoxide generation and platelet aggregation in experimental myocardial ischemia and reflow.
    Röth E; Matos G; Guarnieri C; Papp B; Varga J
    Acta Physiol Hung; 1995; 83(2):163-70. PubMed ID: 8588503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Esmolol in anesthesiology: pharmacology and indications].
    Fita G; Gomar C; Rovira I
    Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esmolol and beta-adrenergic blockade.
    Wolman RL; Fiedler MA
    AANA J; 1991 Dec; 59(6):541-8. PubMed ID: 1686346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
    Mio Y
    Masui; 2006 Jul; 55(7):841-8. PubMed ID: 16856544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
    Covinsky JO
    Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The electrophysiologic properties of esmolol, a short acting beta-blocker.
    Greenspan AM; Spielman SR; Horowitz LN; Laddu A; Senior S
    Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):209-16. PubMed ID: 2900217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia.
    Scorsin M; Mebazaa A; Al Attar N; Medini B; Callebert J; Raffoul R; Ramadan R; Maillet JM; Ruffenach A; Simoneau F; Nataf P; Payen D; Lessana A
    J Thorac Cardiovasc Surg; 2003 May; 125(5):1022-9. PubMed ID: 12771874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esmolol in the treatment of supraventricular tachyarrhythmias.
    Das G; Ferris J
    Can J Cardiol; 1988 May; 4(4):177-80. PubMed ID: 2899451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-ischemia effects of gallopamil and esmolol in an intra-individual comparison in patients with coronary heart disease].
    Mitrovic V; Oehm E; Minge C; Thürmann P; Schlepper M
    Z Kardiol; 1994 Jun; 83(6):431-8. PubMed ID: 7915067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocardial protection: the efficacy of an ultra-short-acting beta-blocker, esmolol, as a cardioplegic agent.
    Bessho R; Chambers DJ
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):993-1003. PubMed ID: 11689806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of an ultra short-acting beta-blocker in patients with acute myocardial ischemia.
    Kirshenbaum JM; Kloner RA; Antman EM; Braunwald E
    Circulation; 1985 Oct; 72(4):873-80. PubMed ID: 2863013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
    Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
    J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of esmolol on oxidant status and antioxidant activity in acute myocardial infarction.
    Daga MK; Chaudhary M; Sharma B; Bhattacharjee J; Ghambhir DS; Arora N; Sudha R
    J Assoc Physicians India; 2003 Jul; 51():677-80. PubMed ID: 14621036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.